Test Type: CHRONIC Route: DOSED FEED

Species/Strain: MICE/B6C3F1/N

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)

Tris(Chloropropyl)phosphate **CAS Number:** 13674-84-5

Date Report Requested: 09/14/2020 Time Report Requested: 10:18:26 First Dose M/F: 10/25/11 / 10/24/11

Lab: BAT

Final 2_Mice

NTP Study Number: C20712

Lock Date: 02/26/2018

Cage Range: ALL

Date Range: ALL

Reasons For Removal: ALL

Removal Date Range: ALL

Treatment Groups: Include ALL

Study Gender: Both

TDMSE Version: 3.0.2.3_002

PWG Approval Date: NONE

Test Type: CHRONIC Route: DOSED FEED

Species/Strain: MICE/B6C3F1/N

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)

Tris(Chloropropyl)phosphate **CAS Number:** 13674-84-5

Date Report Requested: 09/14/2020 Time Report Requested: 10:18:26 First Dose M/F: 10/25/11 / 10/24/11

| B6C3F1/N MICE MALE | 0 ppm males | 1250 ppm males | 2500 ppm males | 5000 ppm males |
|--------------------------------------|-------------|----------------|----------------|----------------|
| Disposition Summary | | | | |
| Animals Initially In Study | 50 | 50 | 50 | 50 |
| Early Deaths | | | | |
| Moribund Sacrifice | 1 | 1 | 1 | 3 |
| Natural Death | 10 | 5 | 7 | 3 |
| Survivors | | | | |
| Natural Death | 1 | | | 1 |
| Terminal Sacrifice | 38 | 44 | 42 | 43 |
| Animals Examined Microscopically | 50 | 50 | 50 | 50 |
| ALIMENTARY SYSTEM | | | | |
| Esophagus | (50) | (50) | (50) | (50) |
| Gallbladder | (50) | (50) | (46) | (50) |
| Intestine Large, Cecum | (50) | (49) | (50) | (50) |
| Intestine Large, Colon | (50) | (50) | (50) | (50) |
| Intestine Large, Rectum | (50) | (50) | (50) | (50) |
| Intestine Small, Duodenum | (50) | (50) | (50) | (50) |
| Intestine Small, Ileum | (50) | (50) | (50) | (50) |
| Diverticulum | | | , , | 1 (2%) |
| Intestine Small, Jejunum | (50) | (50) | (50) | (50) |
| Liver | (50) | (50) | (50) | (50) |
| Basophilic Focus | 4 (8%) | 4 (8%) | 3 (6%) | 2 (4%) |
| Clear Cell Focus | 13 (26%) | 18 (36%) | 12 (24%) | 8 (16%) |
| Eosinophilic Focus | 13 (26%) | 16 (32%) | 9 (18%) | 15 (30%) |
| Fatty Change, Focal | 3 (6%) | 4 (8%) | 1 (2%) | , , |
| Mixed Cell Focus | ` , | 2 (4%) | 1 (2%) | 1 (2%) |
| Necrosis | 10 (20%) | 8 (16%) | 9 (18%) | 8 (16%) |
| Hepatocyte, Cytoplasmic Alteration | 1 (2%) | • • | 2 (4%) | . , |
| Hepatocyte, Vacuolation, Cytoplasmic | ` , | | 1 (2%) | |
| Mesentery | (1) | (1) | (1) | (2) |
| Fat, Necrosis | 1 (100%) | . , | . , | |
| Pancreas | (50) | (50) | (50) | (50) |
| Salivary Glands | (50) | (50) | (50) | (50) |
| Stomach, Forestomach | (50) | (50) | (50) | (50) |

a - Number of animals examined microscopically at site and number of animals with lesion

Test Type: CHRONIC Route: DOSED FEED

Species/Strain: MICE/B6C3F1/N

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)

Tris(Chloropropyl)phosphate **CAS Number:** 13674-84-5

Date Report Requested: 09/14/2020 Time Report Requested: 10:18:26 First Dose M/F: 10/25/11 / 10/24/11

Lab: BAT

| B6C3F1/N MICE MALE | 0 ppm males | 1250 ppm males | 2500 ppm males | 5000 ppm males | |
|--------------------------------|-------------|----------------|----------------|----------------|--|
| Cyst, Squamous | | | | 1 (2%) | |
| Inflammation, Suppurative | | | 1 (2%) | | |
| Ulcer | | | 1 (2%) | | |
| Epithelium, Hyperplasia, Focal | 1 (2%) | | 1 (2%) | 1 (2%) | |
| Stomach, Glandular | (50) | (50) | (50) | (50) | |
| CARDIOVASCULAR SYSTEM | | | | | |
| Blood Vessel | (50) | (49) | (49) | (49) | |
| Heart | (50) | (50) | (50) | (50) | |
| Cardiomyopathy | 1 (2%) | | | | |
| Polyarteritis Nodosa | 1 (2%) | | | | |
| ENDOCRINE SYSTEM | | | | | |
| Adrenal Cortex | (50) | (50) | (50) | (49) | |
| Hyperplasia, Focal | 1 (2%) | 1 (2%) | | 3 (6%) | |
| Hypertrophy, Focal | 14 (28%) | 20 (40%) | 11 (22%) | 6 (12%) | |
| Inflammation, Suppurative | | | 1 (2%) | | |
| Necrosis | | 1 (2%) | | | |
| Bilateral, Hypertrophy, Focal | | 2 (4%) | | | |
| Adrenal Medulla | (50) | (50) | (50) | (49) | |
| Necrosis | | 1 (2%) | | | |
| Islets, Pancreatic | (50) | (50) | (50) | (50) | |
| Parathyroid Gland | (42) | (45) | (46) | (46) | |
| Pituitary Gland | (50) | (46) | (48) | (50) | |
| Pars Distalis, Hyperplasia | | 1 (2%) | | | |
| Pars Intermedia, Hyperplasia | 1 (2%) | 4 | <i>i</i> =-> | () | |
| Thyroid Gland | (50) | (50) | (50) | (50) | |

GENERAL BODY SYSTEM

None

a - Number of animals examined microscopically at site and number of animals with lesion

Test Type: CHRONIC Route: DOSED FEED

Species/Strain: MICE/B6C3F1/N

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)

Tris(Chloropropyl)phosphate **CAS Number:** 13674-84-5

Date Report Requested: 09/14/2020 Time Report Requested: 10:18:26 First Dose M/F: 10/25/11 / 10/24/11

| B6C3F1/N MICE MALE | 0 ppm males | 1250 ppm males | 2500 ppm males | 5000 ppm males | |
|--------------------------------------|-------------|----------------|----------------|----------------|--|
| GENITAL SYSTEM | | | | | |
| Epididymis | (50) | (50) | (50) | (50) | |
| Preputial Gland | (50) | (50) | (50) | (50) | |
| Duct, Dilation | () | () | () | 1 (2%) | |
| Prostate | (50) | (50) | (50) | (50) | |
| Inflammation, Suppurative | 1 (2%) | (5-5) | 2 (4%) | (33) | |
| Seminal Vesicle | (50) | (50) | (50) | (50) | |
| Atrophy | (/ | (/ | 1 (2%) | 1 (2%) | |
| Inflammation, Suppurative | | | 1 (2%) | . (=, | |
| Testis | (50) | (50) | (50) | (50) | |
| Germinal Epithelium, Atrophy | 1 (2%) | (55) | 2 (4%) | 1 (2%) | |
| | | | | | |
| HEMATOPOIETIC SYSTEM | | | | | |
| Bone Marrow | (50) | (50) | (50) | (50) | |
| Hypocellularity | | | 1 (2%) | | |
| Lymph Node | (4) | (3) | (4) | (3) | |
| Mediastinal, Hyperplasia, Lymphocyte | | 1 (33%) | | | |
| Lymph Node, Mandibular | (47) | (50) | (50) | (50) | |
| Lymph Node, Mesenteric | (49) | (49) | (50) | (49) | |
| Congestion | 1 (2%) | | | 1 (2%) | |
| Extramedullary Hematopoiesis | 1 (2%) | | 1 (2%) | | |
| Spleen | (50) | (50) | (50) | (50) | |
| Erythrophagocytosis | | | 1 (2%) | | |
| Extramedullary Hematopoiesis | 23 (46%) | 21 (42%) | 18 (36%) | 20 (40%) | |
| Hyperplasia, Lymphocyte | ` , | | 1 (2%) | 1 (2%) | |
| Thymus | (46) | (47) | (49) | (46) | |
| Atrophy | 1 (2%) | 1 (2%) | 2 (4%) | 1 (2%) | |
| Inflammation, Granulomatous | ` , | . , | 1 (2%) | | |
| INTEGUMENTARY SYSTEM | | | | | |
| Skin | (50) | (50) | (50) | (50) | |

a - Number of animals examined microscopically at site and number of animals with lesion

Test Type: CHRONIC Route: DOSED FEED

Species/Strain: MICE/B6C3F1/N

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)

Tris(Chloropropyl)phosphate **CAS Number:** 13674-84-5

Date Report Requested: 09/14/2020 Time Report Requested: 10:18:26 First Dose M/F: 10/25/11 / 10/24/11

| B6C3F1/N MICE MALE | 0 ppm males | 1250 ppm males | 2500 ppm males | 5000 ppm males | |
|---|-------------|------------------|----------------|----------------|--|
| | | | | | |
| MUSCULOSKELETAL SYSTEM | | | | | |
| Bone Femur, Increased Bone | (50) | (50) | (50) | (49) 1 (2%) | |
| Skeletal Muscle | (1) | (0) | (1) | (0) | |
| NERVOUS SYSTEM | | | | | |
| Brain | (50) | (50) | (50) | (50) | |
| Meninges, Polyarteritis Nodosa | 1 (2%) | | | | |
| RESPIRATORY SYSTEM | | | | | |
| Lung | (50) | (50) | (50) | (50) | |
| Infiltration Cellular, Histiocyte Inflammation, Granulomatous | 1 (2%) | 1 (2%) 1 (2%) | 1 (2%) | | |
| Alveolus, Epithelium, Hyperplasia | 1 (2%) | 1 (270) | 3 (6%) | 1 (2%) | |
| Nose | (50) | (50) | (50) | (50) | |
| Trachea | (50) | (50) | (49) | (50) | |
| SPECIAL SENSES SYSTEM | | | | | |
| Eye | (50) | (50) | (50) | (50) | |
| Phthisis Bulbi | | | 1 (2%) | | |
| Harderian Gland | (50) | (50) | (50) | (50) | |
| Hyperplasia | 2 (4%) | 1 (2%) | 3 (6%) | 1 (2%) | |
| URINARY SYSTEM | | | | | |
| Kidney | (49) | (50) | (50) | (50) | |
| Infarct | | | 1 (2%) | | |
| Metaplasia, Osseous | 1 (2%) | 1 (2%) | 1 (2%) | 1 (2%) | |

Test Type: CHRONIC Route: DOSED FEED

Species/Strain: MICE/B6C3F1/N

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)

Tris(Chloropropyl)phosphate **CAS Number:** 13674-84-5

Date Report Requested: 09/14/2020 Time Report Requested: 10:18:26 First Dose M/F: 10/25/11 / 10/24/11

| B6C3F1/N MICE MALE | 0 ppm males | 1250 ppm males | 2500 ppm males | 5000 ppm males |
|--------------------------------------|-------------|----------------|----------------|----------------|
| Nephropathy, Chronic Progressive | 40 (82%) | 45 (90%) | 43 (86%) | 45 (90%) |
| Pigment | | | 1 (2%) | |
| Capsule, Inflammation, Suppurative | | | 1 (2%) | |
| Papilla, Cyst | | | 1 (2%) | |
| Renal Tubule, Cyst | 1 (2%) | | | |
| Renal Tubule, Cytoplasmic Alteration | | 28 (56%) | 40 (80%) | 48 (96%) |
| Urinary Bladder | (49) | (48) | (50) | (50) |

^{***} END OF MALE ***

Test Type: CHRONIC Route: DOSED FEED

Species/Strain: MICE/B6C3F1/N

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)

Tris(Chloropropyl)phosphate **CAS Number:** 13674-84-5

Date Report Requested: 09/14/2020 Time Report Requested: 10:18:26 First Dose M/F: 10/25/11 / 10/24/11

| B6C3F1/N MICE FEMALE | 0 ppm females | 2500 ppm females | 5000ppm females | 10000ppm females |
|--------------------------------------|---------------|------------------|-----------------|------------------|
| Disposition Summary | | | | |
| Animals Initially In Study | 50 | 50 | 50 | 50 |
| Early Deaths | | | | |
| Moribund Sacrifice | 1 | 2 | 1 | 1 |
| Natural Death | 3 | 5 | 4 | 3 |
| Survivors | | | | |
| Terminal Sacrifice | 46 | 43 | 45 | 46 |
| Animals Examined Microscopically | 50 | 50 | 50 | 50 |
| ALIMENTARY SYSTEM | | | | |
| Esophagus | (50) | (50) | (50) | (49) |
| Gallbladder | (48) | (48) | (50) | (50) |
| Intestine Large, Cecum | (50) | (50) | (50) | (50) |
| Intestine Large, Colon | (50) | (50) | (50) | (50) |
| Intestine Large, Rectum | (50) | (50) | (50) | (50) |
| Intestine Small, Duodenum | (50) | (50) | (50) | (50) |
| Intestine Small, Ileum | (50) | (50) | (50) | (50) |
| Intestine Small, Jejunum | (50) | (50) | (50) | (50) |
| Hyperplasia, Lymphocyte | | 1 (2%) | | |
| Liver | (50) | (50) | (50) | (50) |
| Basophilic Focus | 2 (4%) | 1 (2%) | 5 (10%) | 2 (4%) |
| Clear Cell Focus | 3 (6%) | 2 (4%) | 3 (6%) | 8 (16%) |
| Eosinophilic Focus | 1 (2%) | 7 (14%) | 13 (26%) | 16 (32%) |
| Fatty Change, Focal | 1 (2%) | | 1 (2%) | |
| Inflammation, Chronic Active | | 1 (2%) | | |
| Mixed Cell Focus | | | | 1 (2%) |
| Necrosis | 11 (22%) | 8 (16%) | 5 (10%) | 3 (6%) |
| Pigment | 1 (2%) | | | |
| Bile Duct, Cyst | | 1 (2%) | | 1 (2%) |
| Bile Duct, Cyst, Multiple | | | 1 (2%) | |
| Hepatocyte, Cytoplasmic Alteration | | | 2 (4%) | 48 (96%) |
| Hepatocyte, Vacuolation, Cytoplasmic | 2 (4%) | | | |
| Stellate Cell, Hyperplasia | | 1 (2%) | | |
| Mesentery | (4) | (3) | (3) | (0) |

a - Number of animals examined microscopically at site and number of animals with lesion

Test Type: CHRONIC Route: DOSED FEED

Species/Strain: MICE/B6C3F1/N

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)

Tris(Chloropropyl)phosphate **CAS Number:** 13674-84-5

Date Report Requested: 09/14/2020 Time Report Requested: 10:18:26 First Dose M/F: 10/25/11 / 10/24/11

| B6C3F1/N MICE FEMALE | 0 ppm females | 2500 ppm females | 5000ppm females | 10000ppm females | |
|---------------------------------------|---------------|------------------|-----------------|------------------|--|
| Fat, Necrosis | 4 (100%) | 3 (100%) | 3 (100%) | | |
| Pancreas | (50) | (50) | (50) | (50) | |
| Cyst | | 2 (4%) | 1 (2%) | 1 (2%) | |
| Acinus, Atrophy | 1 (2%) | | | | |
| Acinus, Hyperplasia | | | | 1 (2%) | |
| Salivary Glands | (50) | (49) | (49) | (48) | |
| Stomach, Forestomach | (50) | (50) | (50) | (50) | |
| Epithelium, Hyperplasia | | | | 1 (2%) | |
| Stomach, Glandular | (50) | (50) | (50) | (50) | |
| Epithelium, Hyperplasia | 1 (2%) | , , | ` ' | . , | |
| CARDIOVASCULAR SYSTEM | | | | | |
| Blood Vessel | (50) | (50) | (50) | (50) | |
| Heart | (50) | (50) | (50) | (50) | |
| Fibrosis | | | | 1 (2%) | |
| Infiltration Cellular, Mixed Cell | | | | 1 (2%) | |
| Polyarteritis Nodosa | 2 (4%) | 1 (2%) | | | |
| Epicardium, Inflammation, Suppurative | | 1 (2%) | | | |
| Myocardium, Mineral | 1 (2%) | | | | |
| Myocardium, Necrosis | , | | 1 (2%) | | |
| Valve, Degeneration | | 1 (2%) | 1 (2%) | | |
| Valve, Mineral | | 1 (2%) | , | | |
| ENDOCRINE SYSTEM | | | | | |
| Adrenal Cortex | (50) | (50) | (50) | (50) | |
| Degeneration, Cystic | 1 (2%) | | | | |
| Hyperplasia, Focal | | 1 (2%) | 1 (2%) | | |
| Hypertrophy, Focal | 1 (2%) | | 1 (2%) | 1 (2%) | |
| Vacuolation, Cytoplasmic | | 1 (2%) | | | |
| Adrenal Medulla | (50) | (50) | (50) | (49) | |
| Hyperplasia, Focal | 1 (2%) | | 1 (2%) | | |
| Islets, Pancreatic | (50) | (50) | (50) | (50) | |
| Parathyroid Gland | (43) | (42) | (41) | (43) | |

Test Type: CHRONIC Route: DOSED FEED

Species/Strain: MICE/B6C3F1/N

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)

Tris(Chloropropyl)phosphate **CAS Number:** 13674-84-5

Date Report Requested: 09/14/2020 Time Report Requested: 10:18:26 First Dose M/F: 10/25/11 / 10/24/11

| B6C3F1/N MICE FEMALE | 0 ppm females | 2500 ppm females | 5000ppm females | 10000ppm females |
|-----------------------------------|---------------|------------------|-----------------|------------------|
| Hyperplasia | | | 1 (2%) | |
| Pituitary Gland | (50) | (50) | (50) | (49) |
| Pars Distalis, Hyperplasia | 17 (34%) | 5 (10%) | 4 (8%) | 4 (8%) |
| Pars Intermedia, Hyperplasia | 1 (2%) | | | |
| Thyroid Gland | (49) | (50) | (50) | (48) |
| GENERAL BODY SYSTEM | | | | |
| None | | | | |
| GENITAL SYSTEM | | | | |
| Clitoral Gland | (50) | (50) | (49) | (49) |
| Ovary | (49) | (50) | (50) | (49) |
| Hemorrhage | ` ' | , | 1 (2%) | , , |
| Follicle, Cyst | 8 (16%) | 9 (18%) | 6 (12%) | 11 (22%) |
| Rete Ovarii, Cyst | , , | 2 (4%) | , , | , , |
| Uterus | (50) | (50) | (50) | (50) |
| Adenomyosis | ` ' | ` ' | ` ' | 1 (2%) |
| Dilation | 13 (26%) | 18 (36%) | 10 (20%) | 8 (16%) |
| Inflammation, Suppurative | 3 (6%) | 1 (2%) | (/ | 1 (2%) |
| Cervix, Inflammation, Suppurative | - (- · - / | 1 (2%) | | 1 (2%) |
| Cervix, Metaplasia, Mucous Cell | 1 (2%) | , , | | , |
| Endometrium, Hyperplasia, Cystic | 45 (90%) | 41 (82%) | 41 (82%) | 40 (80%) |
| Vagina | (0) | (0) | (1) | (0) |
| HEMATOPOIETIC SYSTEM | | | | |
| Bone Marrow | (50) | (50) | (50) | (50) |
| Fibrosis | () | 2 (4%) | (/ | 1 (2%) |
| Lymph Node | (4) | (5) | (5) | (3) |
| Hyperplasia, Lymphocyte | (· / | 1 (20%) | (0) | (-) |
| Lumbar, Hemorrhage | 1 (25%) | . (==,,, | | |
| Lymph Node, Mandibular | (50) | (50) | (48) | (48) |
| =,, | (00) | (30) | (10) | (10) |

a - Number of animals examined microscopically at site and number of animals with lesion

Test Type: CHRONIC Route: DOSED FEED

Species/Strain: MICE/B6C3F1/N

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)

Tris(Chloropropyl)phosphate **CAS Number:** 13674-84-5

Date Report Requested: 09/14/2020 Time Report Requested: 10:18:26 First Dose M/F: 10/25/11 / 10/24/11

| B6C3F1/N MICE FEMALE | 0 ppm females | 2500 ppm females | 5000ppm females | 10000ppm females | |
|--|---------------|------------------|-----------------|------------------|--|
| Hyperplasia, Lymphocyte | 25 (50%) | 22 (44%) | 25 (52%) | 33 (69%) | |
| Lymph Node, Mesenteric | (49) | (49) | (50) | (49) | |
| Hemorrhage | 1 (2%) | | | | |
| Hyperplasia, Lymphocyte | 35 (71%) | 26 (53%) | 27 (54%) | 35 (71%) | |
| Hyperplasia, Plasma Cell | | | | 1 (2%) | |
| Spleen | (49) | (49) | (50) | (50) | |
| Extramedullary Hematopoiesis | 10 (20%) | 11 (22%) | 20 (40%) | 13 (26%) | |
| Hyperplasia, Lymphocyte | 38 (78%) | 36 (73%) | 31 (62%) | 39 (78%) | |
| White Pulp, Atrophy | | | | 1 (2%) | |
| Thymus | (48) | (48) | (47) | (48) | |
| Atrophy | 3 (6%) | 5 (10%) | 3 (6%) | | |
| Hyperplasia, Lymphocyte | 18 (38%) | 16 (33%) | 17 (36%) | 16 (33%) | |
| INTEGUMENTARY SYSTEM | | | | | |
| Mammary Gland | (50) | (49) | (50) | (50) | |
| Skin | (50) | (50) | (50) | (50) | |
| MUSCULOSKELETAL SYSTEM | | | | | |
| Bone | (50) | (50) | (50) | (50) | |
| Femur, Fibro-Osseous Lesion | (00) | 2 (4%) | (00) | 1 (2%) | |
| Skeletal Muscle | (0) | (1) | (1) | (0) | |
| NERVOUS SYSTEM | | | | | |
| Brain | (50) | (50) | (50) | (50) | |
| Cyst Epithelial Inclusion | (/ | (/ | 1 (2%) | (/ | |
| Inflammation, Suppurative | | 1 (2%) | . (-,0) | | |
| Meninges, Infiltration Cellular, Mononuclear Cell | 2 (4%) | (= /0) | | 1 (2%) | |
| Neuron, Necrosis | 1 (2%) | 1 (2%) | 1 (2%) | | |
| Thalamus, Fibrosis | ` ' | 1 (2%) | , | | |

a - Number of animals examined microscopically at site and number of animals with lesion

Test Type: CHRONIC **Route:** DOSED FEED

Species/Strain: MICE/B6C3F1/N

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)

Tris(Chloropropyl)phosphate **CAS Number:** 13674-84-5

Date Report Requested: 09/14/2020 Time Report Requested: 10:18:26 First Dose M/F: 10/25/11 / 10/24/11

Lab: BAT

| B6C3F1/N MICE FEMALE | 0 ppm females | 2500 ppm females | 5000ppm females | 10000ppm females | |
|---|---------------|------------------|-----------------|------------------|--|
| RESPIRATORY SYSTEM | | | | | |
| Lung | (50) | (50) | (50) | (50) | |
| Infiltration Cellular, Histiocyte | 1 (2%) | | | | |
| Inflammation, Granulomatous | | 1 (2%) | | | |
| Pigment | | | | 1 (2%) | |
| Alveolus, Epithelium, Hyperplasia | 1 (2%) | | | | |
| Nose | (50) | (50) | (50) | (50) | |
| Trachea | (50) | (50) | (50) | (49) | |
| SPECIAL SENSES SYSTEM | | | | | |
| Eye | (50) | (50) | (50) | (50) | |
| Posterior Chamber, Inflammation, Chronic Active | (, | (==/ | 1 (2%) | () | |
| Harderian Gland | (50) | (50) | (50) | (50) | |
| Atrophy | | | 1 (2%) | | |
| Hyperplasia | 2 (4%) | | 2 (4%) | 1 (2%) | |
| URINARY SYSTEM | | | | | |
| Kidney | (50) | (50) | (50) | (49) | |
| Metaplasia, Osseous | 1 (2%) | , | , | , | |
| Nephropathy, Chronic Progressive | 13 (26%) | 13 (26%) | 11 (22%) | 13 (27%) | |
| Left, Atrophy | | | 1 (2%) | | |
| Papilla, Inflammation, Suppurative | | | 1 (2%) | | |
| Papilla, Necrosis | | | 1 (2%) | | |
| Renal Tubule, Necrosis | | | 1 (2%) | | |
| Urinary Bladder | (49) | (49) | (50) | (49) | |
| Degeneration | 1 (2%) | | | | |

*** END OF REPORT ***

a - Number of animals examined microscopically at site and number of animals with lesion